Ultragenyx Pharma Is Maintained at Neutral by Goldman Sachs

What happened

Goldman Sachs maintained its Neutral rating on Ultragenyx Pharma, meaning it did not change its rating, and cut its price target to $17.00 per share from $19.00. The supplied report identifies this as an analyst rating action but gives no reason for the change.

Confirmed

Global impact / market context

The lower target signals that Goldman Sachs now sees less potential value in Ultragenyx shares than before, although the unchanged Neutral rating indicates no change in its stated rating category. Investors may reassess expected returns, while the report provides no details about business performance or the reasons behind the cut.

Analyst inference

This is an analyst opinion, not a reported change in Ultragenyx’s revenue, costs, or cash available. The target reduction could influence investor expectations or positioning in the shares, but the supplied information does not establish any market reaction or explain what prompted Goldman Sachs’ action.

Analyst inference

What to watch

1. Check whether Goldman Sachs issues another rating action on Ultragenyx Pharma; a new rating or target would show whether its view has changed from Neutral and the $17 target. Analyst inference
2. Look for a company announcement explaining business developments that could inform Goldman Sachs’s lower target; this report provides no reason for the cut. Analyst inference
3. Compare any later Goldman Sachs target with its previous $19 target and the reported $17 target to see whether its stated view continues to change. Analyst inference

Evidence

• Original source link unavailable